Microdosing Ketamine for Health & Longevity - Quick Reference Sheet

Microdosing Ketamine for Health & Longevity

Created on 09/30/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Microdosing ketamine means taking small, spaced oral doses of a prescription anesthetic at home, hoping to lift mood and keep the brain adaptable. In depression, repeated low oral doses reduced symptoms in small controlled studies; the tiniest doses rest mostly on patient reports, and benefit for adults without depression remains largely untested. Harms appear uncommon at small doses, but heavy or unsupervised use risks dependence and bladder damage. (Full Review)

Protocol

Very-low-dose sublingual ("microdosing")
10 mg every 2–3 days or weekly
Held sublingually for about 5 minutes, then swallowed
Low-dose oral per-kilogram dosing
0.5–1 mg/kg two to three times weekly
About 35–70 mg at 70 kg, for three weeks in academic trials
Time of day
Late afternoon or evening
At home, lying down; no driving until the next day after restful sleep
Time to effect
Depressive symptoms
By the second week
Repeated low oral doses in depression trials; very-low-dose sublingual users report effects within days
Suicidal thoughts
Within one day
After a single intravenous infusion, lasting up to a week; untested at microdoses
Anxiety
Within an hour
After subcutaneous (under-the-skin) doses of 0.25–1 mg/kg in treatment-resistant social and generalized anxiety

Benefits

Contraindications
  • History of psychosis, schizophrenia-spectrum disorder, or bipolar I disorder with mania in the past 12 months
  • Current or past substance use disorder (moderate or severe), especially involving ketamine, stimulants or alcohol
  • Blood pressure above 140/90 mmHg before dosing despite treatment
  • Aneurysmal vascular disease (ballooned artery walls), arteriovenous malformation (abnormal artery-vein tangle) or prior intracerebral hemorrhage (bleeding within the brain)
  • Myocardial infarction (heart attack) within the past 6 weeks, unstable angina (chest pain at rest), or heart failure (New York Heart Association class III–IV)
  • Pregnancy, planned pregnancy or breastfeeding
  • Liver impairment (Child-Pugh class C, severe cirrhosis), or liver enzymes above 3 times the upper limit of normal
  • Interstitial cystitis (chronic bladder inflammation) or unexplained lower urinary tract symptoms
  • Age under 18
Key Interactions
  • Alcohol and cannabis: Avoid. Additive sedation and dissociation
  • Driving and operating machinery: Avoid. Impaired attention and coordination
  • Benzodiazepines (lorazepam, alprazolam, clonazepam): Caution. Additive sedation and falls
  • Opioids (oxycodone, morphine, fentanyl): Caution. Additive sedation and respiratory depression
  • Stimulants and MAOIs (monoamine oxidase inhibitors, an older class of antidepressants; amphetamine, methylphenidate, phenelzine): Caution. Additive blood-pressure and heart-rate rise
  • Dextromethorphan (cough suppressants): Caution. Dizziness and dissociation
  • Sedating antihistamines (diphenhydramine, doxylamine): Caution. Additive sedation
  • Decongestants (pseudoephedrine, phenylephrine): Caution. Additive blood-pressure rise
  • Sedating supplements (kava, valerian, high-dose melatonin): Caution. Additive sedation
  • Yohimbine and high-dose caffeine: Caution. Additive blood-pressure and heart-rate rise
  • Opioid antagonists (naltrexone, including low-dose naltrexone): Monitor. Blunted antidepressant effect
  • CYP3A4 inhibitors (clarithromycin, grapefruit juice): Monitor. Intensified sedation and dissociation
  • CYP2B6 inhibitors (ticlopidine, clopidogrel): Monitor. Raised exposure and drowsiness
  • Lamotrigine: Monitor. Reduced perceptual and psychosis-like effects
  • Rapamycin (sirolimus): Monitor. Prolonged antidepressant effect
  • St John's wort: Monitor. Reduced exposure, risking loss of effect
  • Cannabidiol (CBD): Monitor. May raise ketamine levels
  • Magnesium and zinc (natural NMDA modulators): Monitor. Theoretical additive NMDA (glutamate receptor) blockade
  • Psychotherapy: No safety concern (potentiating)

Risk & Side Effects

  • High: Dissociation and perceptual disturbances; dizziness, headache, nausea and sedation; transient rise in blood pressure and heart rate
  • Medium: Bladder and urinary tract damage
  • Low: Misuse, dependence and tolerance; liver injury; bile duct injury; cognitive impairment with frequent use; mood worsening with heavy use
  • Speculative: Neurotoxicity; opposing mTOR-targeting longevity strategies

Monitoring

Marker Target Why
Blood pressure Below 120/80 mmHg at rest Detect ketamine-induced rises
Resting heart rate 50–70 beats per minute Detect fight-or-flight stimulation
ALT (alanine aminotransferase) Below 25 U/L Early liver injury
GGT (gamma-glutamyl transferase) Below 25 U/L Bile-flow (cholestatic) injury
Urinalysis (blood, white cells, protein) Negative for all Early bladder irritation
Creatinine and eGFR (estimated glomerular filtration rate) eGFR above 90 mL/min/1.73 m² Upper urinary tract involvement
PHQ-9 (Patient Health Questionnaire-9) Below 5 Track mood benefit
GAD-7 (Generalized Anxiety Disorder-7) Below 5 Track anxiety benefit
CYP2B6 genotype (optional, once) No established target; record *1/*1, *1/*6 or *6/*6 Identify slow metabolizers

Cadence: Baseline before the first dose; blood pressure before and 60 minutes after each of the first three doses; symptom questionnaires weekly for the first 4 weeks; laboratory tests at 4 weeks, then every 3 months while dosing continues; urinary symptoms at every session

Qualitative Assessment

  • Mood stability and emotional resilience across the week
  • Sleep quality, dream intensity and next-morning alertness
  • Energy and motivation on non-dosing days
  • Cognitive clarity, memory and focus
  • Intensity of dissociation or dizziness after each dose
  • New urinary frequency, urgency or discomfort
  • Craving, or any urge to increase dose or frequency